Back to top
more

Protalix BioTherapeutics (PLX)

(Delayed Data from AMEX)

$1.14 USD

1.14
260,806

-0.02 (-1.72%)

Updated Jun 14, 2024 03:59 PM ET

After-Market: $1.15 +0.01 (0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Protalix BioTherapeutics, Inc. [PLX]

Reports for Purchase

Showing records 21 - 40 ( 77 total )

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

09/24/2018

Company Report

Pages: 5

Preliminary BRIDGE Study Data Indicate Potential Superiority of PRX-102 vs. Replagal; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

08/13/2018

Company Report

Pages: 4

2Q 2018 Financial Results Reported; Top- and Bottom-Line Miss; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

07/25/2018

Company Report

Pages: 4

PRX-102 Partnered in U.S. With Chiesi; Reiterate Buy and Reducing Target to $4

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

06/11/2018

Company Report

Pages: 4

Additional OPRX-106 Phase 2a Data Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

05/11/2018

Company Report

Pages: 4

1Q 2018 Results Reported; Revenue Beat; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

03/14/2018

Company Report

Pages: 4

Complete Top-Line Data Reported From Phase 2 OPRX-106 Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

03/07/2018

Company Report

Pages: 4

4Q and FY2017 Results Reported; Fabry Program Should Complete Enrollment in 2018; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

02/16/2018

Company Report

Pages: 4

OPRX-106 Trial Patient Dosing Complete; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

02/12/2018

Company Report

Pages: 5

WORLDSymposium Data Strengthen Case for PRX-102 in Fabry Disease; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

02/01/2018

Company Report

Pages: 5

PRX-102 Receives FDA Fast Track Designation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

01/04/2018

Company Report

Pages: 4

Positive Interim Data Reported in Ulcerative Colitis; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

11/29/2017

Company Report

Pages: 5

Positive Incremental Phase 1/2 Data for PRX-102; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

11/09/2017

Company Report

Pages: 5

3Q17 Financial Results Reported; Chiesi Partnership Reduces Risk; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

08/10/2017

Company Report

Pages: 4

2Q17 Financial Results Reported; Clinical Progress Continues; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

08/10/2017

Company Report

Pages: 4

2Q17 Financial Results Reported; Clinical Progress Continues; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

07/12/2017

Company Report

Pages: 5

Additional Cystic Fibrosis Data Presented; Multi-Product Facility Authorized; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

07/12/2017

Company Report

Pages: 5

Additional Cystic Fibrosis Data Presented; Multi-Product Facility Authorized; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

05/15/2017

Company Report

Pages: 4

1Q Financials Reported; Brazilian Elelyso Demand Coming Online; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

05/15/2017

Company Report

Pages: 4

1Q Financials Reported; Brazilian Elelyso Demand Coming Online; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

04/17/2017

Company Report

Pages: 5

AIR DNase Demonstrates Potential; Raising Price Target

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party